Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY (

05 AUG -9

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name				-	3
Acader	ny of Managed Care I	Pharmac	у	·	
2. Address Check if	different than previously repo	orted	-		
100 North Pitt Str	eet, Suite 400				
Alexandria		V	4	22314	US
3. Principal place of business (if differ	rent than line 2)				4400
City		State/Zip	or Country		
4a. Contact Name	b. Telephone number		c. E-mail	***************************************	5. Senate ID#
	703.683.8416	bherr	nelin@amcp.org		4879312
7. Client Name Self Academy of Managed Care	[⊃] harmacy				6. House ID # 34506000
TYPE OF REPORT 8. Year	2005 Midyea	ar (January	1-June30)	OR Yea	r End (July 1-December
9. Check if this filing amends a previo	usly filed version of this re	eport []		
10. Check if this is a Termination Repo	ort 🔲 Terminat	tion Date_			11. No Lobbying Activ
INCOME OR EXPENSES	- Complete Either	Line 12	OR Line 13		
12. Lobbyin	g Firms			13. Organ	izations
INCOME relating to lobbying activiti was:	es for this reporting period	i	EXPENSES relating to lobbying activities for this report were:		
Less than \$10,000			Less than \$10,000		
\$10,000 or more □ ⇒ \$		-	\$10,000 or more	⊠ ⇔ \$	100,000
Provide a good faith estimate, roun					eck box to indicate exper s for description of optio
of all lobbying related income from payments to the registrant by any o activities on behalf of the client).			Method A.		ts using LDA definitions on
activities on behalf of the elicity.			Method B.	Internal Revenue	ts under section 6033(b)(8) Code
		l	☑ Method C.	Reporting amoun Revenue Code	ts under section 162(e) of th
()00	\/\ \			Δ	Edit >
Signature	Hem		Date	Oleger	18,2005
Printed Name and Title William	n Hermelin			U	

✓ Page 1

Registrant Name Academy of Managed Care Pharmacy	Client Name Academy of Managed Care Pharma
LOBBYING ACTIVITY. Select as many codes as no engaged in lobbying on behalf of the client during the reinformation as requested. Attach additional page(s) as	eporting period. Using a separate page for each cod
15. General issue area code HCR - Health Issues	(one per page)
16. Specific lobbying issues	
Patient Safety and Quality Improvement Act (S544/HI Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Report FDA Improvement Act (S930/HR2090) Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (ing Act (S518/HR1132)
17. House(s) of Congress and Federal agencies contacted	ed Check if None
US Senate US House of Representatives	
18. Name of each individual who acted as a lobbyist in	this issue area
Name	Covered Official Position (if applicable)
William Hermelin	
Cynthia (Cindy) Miller	
Melissa James	
19. Interest of each foreign entity in the specific issues	isted on line 16 above Check if None
Signature (1) Il Hermel	Date Quent 8, 2005

LD-2DS (RIM/03)

Page 2

Registrant Name	Academy of Managed Care Pharmacy		Client Name	Academy of Managed Care Ph	narma	
ABDMor Ge	NDMor GeneralLoling Issu Area		R			
6. Specific lobbying issues (continued from previous page)						
Pharmacy	ce Clause" legislation (HR1539 Benefit Manager Transparenc by Pharmacy Fairness Act (HR1	y Act (HR1669)		•		
				·		
				1	,	
				•		

Registrant Name_	Academy of Managed Care Pharmacy	Client Name Academy of Managed Care Pharm
engaged in lobb	CTIVITY. Select as many codes as necessing on behalf of the client during the represented. Attach additional page(s) as necessited.	essary to reflect the general issue areas in which the orting period. Using a separate page for each conseded.
15. General issu	e area code MMM - Medicare/Medicaid	(one per page)
16. Specific lobb	bying issues	
Labor/HHS A Medicare's E Prescription Medicare Pre	olutions re:Medicare/Medicaid (S.Con.Res. Appropriations (HR3010) Equitable Drugs for Seniors Act (HR376) Drug Affordability Act (HR563) escription Drug Savings and Choice Act (Hescription Drug Improvement Act (HR1626)	R752)
17. House(s) of	Congress and Federal agencies contacted	Check if None
US Senate US House of	Representatives	
18. Name of eacl	h individual who acted as a lobbyist in th	is issue area
	Name	Covered Official Position (if applicable)
William	Hermelin	
Cynthia (Cindy)	Miller	
Melissa	James	
19. Interest of each	ch foreign entity in the specific issues list	

LD-2DS (REV. 4/03)

Page 4

Academy of Managed Care Pharmacy Academy of Managed Care Pharma Registrant Name Client Name **MMM** ANDMor GeneralLolng Issu Area 🔃 16. Specific lobbying issues (continued from previous page) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR2685) Rescinds current MMA exclusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (H.Res.267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (\$18) Efficiency in Government Healthcare Spending Act (S123) Medicare Enhancements for Needed Drugs (\$239) Medicare Prescription Drug Savings and Choice Act (\$345/\$873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (\$1356)

Page 5

	address	Complete ONI	Y where registration info	ermation has change	ed.
21. Client new	principal place of busi	ness (if different the	an line 20)		*********
City			te/Zip		
22. New genera	al description of client'	s business or activit	ites		
LOBBYIST					
23. Name of e	ach previously repor	ted individual wh	o is no longer expected to ac	t as a lobbyist for the cl	ient
Ann	Curry				
ISSUE UPD				· · · · · · · · · · · · · · · · · · ·	
	bbying issues that n o	longer pertain			
CPT					
AFFILIATE	D ORGANIZATI	ONS			
25. Add the fol	llowing affiliated org	anization(s)			
	Name		Address	Principal place of Busines (city and state or countr	

			l		
26. Name of ea	ich previously report	ed organization th	nat is no longer affiliated with	the registrant or clien	
				÷ .	
FOREIGN E	Larring taxaian antiti	Address	Principal place of business	Amount of contribution	Ow
	lowing foreign entiti			for lobbying activities	clie
27. Add the fol	lowing foreign entiti	1**************************************	(city and state or country)		-
27. Add the fol	lowing foreign entiti		(city and state of country)		
27. Add the fol Name					
27. Add the fol Name	th previously reported	foreign entity that n	o longer owns, or controls, or i	s affiliated with the regis	rant,
27. Add the fol Name	th previously reported	foreign entity that n		s affiliated with the regis	rant,
27. Add the fol Name	th previously reported	foreign entity that n		s affiliated with the regis	rant,
27. Add the fol Name	th previously reported	foreign entity that n		s affiliated with the regis	

Filing #bb2f80ca-6dc3-4540-b521-e3caeea38bcf - Page 11 of 12